GATC Health
Provider of an AI-driven multiomics simulation platform that models multi-scale human biology to support therapeutic discovery, in-silico pharmacology, clinical trial simulation, population genomic analysis, and predictive risk analytics for industry, academic, and investor stakeholders. Headquartered in Irvine, CA with additional facilities referenced in Utah, West Virginia, and Washington, D.C.
Industries
Nr. of Employees
small (1-50)
GATC Health
Irvine, California, United States, North America
Products
Multiomics simulation platform
Computational platform that integrates whole-genome and other omics data with machine learning and neural-network simulations to conduct in-silico experiments for therapeutic discovery and clinical prediction.
Standardized predictive risk-reporting service
Service that produces standardized risk reports assessing likelihood of clinical-trial success and asset-level safety/efficacy risks to support capital allocation and underwriting decisions.
Multiomics simulation platform
Computational platform that integrates whole-genome and other omics data with machine learning and neural-network simulations to conduct in-silico experiments for therapeutic discovery and clinical prediction.
Standardized predictive risk-reporting service
Service that produces standardized risk reports assessing likelihood of clinical-trial success and asset-level safety/efficacy risks to support capital allocation and underwriting decisions.
Services
In-silico candidate analysis (efficacy, safety, ADME/Tox)
Computational evaluation of drug candidates to predict pharmacokinetics, toxicology, off-target effects, immune responses, and likely clinical endpoints to inform development decisions.
Population genomic analysis and individualized risk reporting
Processing and interpretation of large-scale genomic and other omics datasets to produce de-identified population insights and individualized predictive health reports for public-health programs.
Predictive risk-reporting for clinical and investment decisions
Delivery of standardized predictive risk intelligence and scoring to de-risk development pipelines and support investor due diligence, portfolio decisions, and clinical-trial insurance underwriting.
Collaborative discovery and platform integration
Partnership-based projects to integrate AI analytics into partner workflows and accelerate target discovery, assay design, and therapeutic optimization.
In-silico candidate analysis (efficacy, safety, ADME/Tox)
Computational evaluation of drug candidates to predict pharmacokinetics, toxicology, off-target effects, immune responses, and likely clinical endpoints to inform development decisions.
Population genomic analysis and individualized risk reporting
Processing and interpretation of large-scale genomic and other omics datasets to produce de-identified population insights and individualized predictive health reports for public-health programs.
Predictive risk-reporting for clinical and investment decisions
Delivery of standardized predictive risk intelligence and scoring to de-risk development pipelines and support investor due diligence, portfolio decisions, and clinical-trial insurance underwriting.
Collaborative discovery and platform integration
Partnership-based projects to integrate AI analytics into partner workflows and accelerate target discovery, assay design, and therapeutic optimization.
Expertise Areas
- Multiomics data integration and simulation
- AI-driven target identification and lead generation
- In-silico pharmacology (PK/ADME) and toxicology prediction
- Clinical trial simulation and predictive risk assessment
Key Technologies
- Deep learning and neural-network biological simulation
- Whole-genome and multiomics data processing
- Protein–ligand interaction prediction models
- In-silico PK/ADME/Tox modeling